MedTrace Logo

THRIVE in Sedated Gastrointestinal Endoscopy

NCT07487051 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2026-03-23

No results posted yet for this study

Summary

This prospective observational study aims to evaluate the effectiveness of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) compared to standard nasal cannula (SNC) oxygen supplementation in patients undergoing elective diagnostic gastroscopy under propofol sedation. The primary outcome is the incidence of hypoxemia (SpO₂ \<93% for ≥20 seconds) during the procedure. Secondary outcomes include the need for airway intervention, Oxygen Reserve Index (ORi) values, peripheral oxygen saturation (SpO₂) levels, and hemodynamic parameters recorded throughout the procedure. Oxygen delivery method was selected by the attending anesthesia provider independent of the study team.

Conditions

  • Hypoxemia
  • Gastrointestinal Endoscopy

Interventions

DEVICE

High-Flow Nasal Oxygen (THRIVE)

Heated and humidified high-flow nasal oxygen was delivered via a THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) system at a flow rate of 30 L/min with FiO₂ of 1.0, initiated 2 minutes prior to propofol induction and maintained continuously until the end of the procedure. The system generates nasopharyngeal positive pressure and reduces dead space, thereby supporting oxygenation and delaying desaturation during apneic episodes.

DEVICE

Standard Nasal Cannula Oxygen

Supplemental oxygen was administered via a standard nasal cannula at a flow rate of 10 L/min, initiated 2 minutes prior to propofol induction and maintained continuously until the end of the procedure. This represents the standard of care for oxygen supplementation during procedural sedation for gastrointestinal endoscopy.

Sponsors & Collaborators

  • Fatih Sultan Mehmet Training and Research Hospital

    lead OTHER

Principal Investigators

  • oznur demiroluk, MD · fatih sultan mehmet research and training hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2025-10-01
Completion
2025-10-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07487051 on ClinicalTrials.gov